Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3545-3557

  Dillman, Robert O ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; PREDNISONE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG EVALUATION; HUMANS; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY;

EID: 0037102128     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.02.126     Document Type: Review

References (89)

1. Cancer statistics, 2001
2. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
3. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997
4. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
5. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes
6. Natural history of and therapy for the indolent non-Hodgkin's lymphomas
7. Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: A progress report
8. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: A Southwest Oncology Group study
9. Combination chemotherapy prolongs survival in follicular mixed lymphoma
10. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma
11. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen
12. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma: Groupe d'Etude des Lymphomes de l'Adulte
13. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809
14. Cyclophosphamide + interferon alpha-2b in follicular low-grade lymphomas: A preliminary report on an intergroup trial (CALGB 8691 and EST 7486)
15. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma: German Low-Grade Lymphoma Study Group
16. Current approaches to therapy for indolent non-Hodgkin's lymphoma
17. New prospects in the treatment of indolent lymphomas with purine analogues
18. Magic bullets at last! Finally - Approval of a monoclonal antibody for the treatment of cancer!!!
19. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
20. Extended rituximab (anti-CD20 monoclonal antibody) therapy in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma
21. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
22. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
23. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
24. Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: Final report
25. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
26. Monoclonal antibodies for treating cancer
27. Radioimmunotherapy: Recent results and future directions
28. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
29. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
30. Principles of radioimmunotherapy for hematologists and oncologists
31. Radioimmunotherapy: Potential as a therapeutic strategy in non-Hodgkin's lymphoma
32. Labeling monoclonal antibodies with halogen nuclides
33. Centralized radiolabeling of antibodies for radioim-munotherapy
34. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients
35. I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images
36. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report
37. Radiolabeled antibody: Iodine versus radiometal chelates
38. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung cancer xenograft
39. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma
40. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution
41. Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma
42. Phase I/II 90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
43. Tumor dosimetry results for Zevalin radioimmunotherapy
44. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia
45. Lack of radioimmunodetection and complications associated with monoclonal anticarcinoembryonic antigen antibody cross-reactivity with an antigen on circulating cells
46. Antibodies as cytotoxic therapy
47. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Update results and long-term follow-up of the University of Michigan experience
48. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
49. Toxicities associated with monoclonal antibody infusions in cancer patients
50. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
51. Infusion reactions associated with the infusion of monoclonal antibodies in the treatment of malignancy
52. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid tumor clearance
53. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with Zevalin™ for non-Hodgkin's lymphoma
54. Hematopoietic stem cell transplantation in lymphoma patients receiving prior therapy with tositumomab and iodine I131 tositumomab (Bexxar™)
55. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
56. Report of an international workshop to standardize response criteria for nonHodgkin's lymphomas: NCI Sponsored International Working Group
57. Results of a randomized trial of Bexxar (tositumomab and iodine I 131 tositumomab) vs unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma
58. Iodine-131 tositumomab for non-Hodgkin's lymphoma patients who progressed after treatment with rituximab: Results of a multicenter phase II study
59. Zevalin™ radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma
60. Iodine I 131 tositumomab for patients with follicular non-Hodgkin's lymphoma: Overall clinical trial experience by histology
61. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory lowgrade and transformed low-grade B-cell non-Hodgkin's lymphomas
62. Iodine 131 tositumomab for patients with transformed low-grade non-Hodgkin's lymphoma: Overall clinical trial experience
63. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell lymphomas
64. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: A phase II multicenter trial
65. Interim safety and efficacy results of Bexxar™ in a large multicenter expanded access study
66. Bexxar™ is a well-tolerated therapy in elderly patients with low-grade or transformed low-grade non-Hodgkin's lymphoma
67. Zevalin radioimmunotherapy can be safely administered to patients with relapsed or refractory B cell non-Hodgkin's lymphoma
68. Zevalin™ radioimmunotherapy is associated with a low infection risk
69. Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens
70. The human antimouse and antiglobulin responses to monoclonal antibodies
71. Human antimouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies
72. Zevalin™ radioimmunotherapy is associated with a low incidence of human-anti mouse antibody (HAMA) and human anti-Rituxan™ antibody (HACA) response
73. Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma
74. Cancer risk after idoine-131 therapy for hyperthyroidism
75. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
76. Outpatient treatment with (131)I-anti-B1 antibody: Radiation exposure to family members
77. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members
78. Family members of patients receiving Zevalin™ radioimmunotherapy do not receive radiation exposure above background levels
79. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy
80. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: Outpatient iodine-131 anti-B1 therapy
81. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stein cell transplantation for relapsed B-cell lymphomas
82. A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800
83. Radiolabeledantibody therapy of B-cell lymphoma with autologous bone marrow support
84. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
85. Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER2
86. Multicenter study of campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine
87. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
88. Monoclonal antibody therapy for lymphoma